IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model
Limited efficacy of immune checkpoint inhibitors in hepatocellular carcinoma (HCC) was observed in clinical trials, thus prompting investigation into combination therapy. Interleukin-6 (IL-6) has important roles in modeling immune responses in cancers. Here, we hypothesized that IL-6 blockade would...
Saved in:
Published in | Biochemical and biophysical research communications Vol. 486; no. 2; pp. 239 - 244 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
29.04.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!